GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

SXTP · Mar 31, 2024

60 DEGREES PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001213900-24-043323General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

128.80% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-979.23% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

373.83% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

43.81% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-1143.42% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

289.52% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

744.73% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/8 normalizedLevel 3 Sep 30, 20240/9 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20254/9 normalizedLevel 3 Sep 30, 20256/9 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20267/9 normalizedLevel 3 Jun 30, 20269/9 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Increased

Previous: 59.15%
Current: 128.80%
Delta: 69.64%

Cash Generation Increased

Previous: -1791.56%
Current: -979.23%
Delta: 812.33%

Inventory Pressure Increased

Previous: 183.84%
Current: 373.83%
Delta: 189.99%

Margin Increased

Previous: -87.15%
Current: 43.81%
Delta: 130.96%

Profitability Increased

Previous: -2032.78%
Current: -1143.42%
Delta: 889.36%

R And D Intensity Increased

Previous: 272.81%
Current: 289.52%
Delta: 16.71%

Sbc Intensity Increased

Previous: 83.84%
Current: 744.73%
Delta: 660.88%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · SXTP Fundamental State →Transitioned To · SXTP Fundamental State →Transitioned To · SXTP BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · SXTP CASH_GENERATION_INCREASED →Transitioned To · SXTP INVENTORY_PRESSURE_INCREASED →Transitioned To · SXTP MARGIN_INCREASED →Transitioned To · SXTP PROFITABILITY_INCREASED →Transitioned To · SXTP R_AND_D_INTENSITY_INCREASED →Transitioned To · SXTP SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.